• CUDC-907: Technical Guidance for Dual PI3K and HDAC Inhibiti

  2026-07-24

  CUDC-907 is a dual PI3K and HDAC inhibitor suited for in vitro research focused on cell signaling, cell cycle arrest, and apoptosis mechanisms in cancer models. It is not validated for diagnostic or therapeutic use, and should be handled strictly according to technical product guidance. Use is appropriate in controlled laboratory workflows but not in clinical or in vivo diagnostic settings.

• Doxycycline in 3D Cell Dynamics: Beyond Antimicrobial Resear

  2026-07-24

  Explore Doxycycline's unique role as a tetracycline antibiotic in modulating stem cell and cancer cell behavior within 3D hydrogels. This article unveils distinct mechanistic insights and advanced research applications, setting it apart from conventional reviews.

• Cinoxacin: Redefining Gram-Negative Infection Research

  2026-07-23

  Explore how Cinoxacin, a quinolone antibiotic from APExBIO, is transforming the landscape of translational research targeting Gram-negative bacterial infections. This thought-leadership article delivers mechanistic insights, experimental strategies, and competitive benchmarking, while elevating the discussion beyond standard product pages with forward-thinking guidance for urinary tract infection and antibiotic resistance studies.

• BMS-345541 Hydrochloride: Precision IKK Inhibitor Protocols

  2026-07-23

  BMS-345541 hydrochloride delivers precise, selective IKK inhibition for inflammation and cancer biology research, optimizing workflows targeting NF-κB-dependent pathways. This guide provides actionable protocol parameters, troubleshooting strategies, and cross-study insights to help researchers maximize assay success.

• Dutasteride as a Dual 5-Alpha-Reductase Inhibitor: Advanced

  2026-07-22

  Dutasteride enables high-precision modeling of androgen-driven mechanisms in prostate cancer and BPH research. This article provides actionable workflow enhancements, protocol specifics, and troubleshooting tips, leveraging APExBIO’s rigorously characterized compound for robust, reproducible results.

• Mavorixafor in WHIM Syndrome: Phase 3 Trial Advances & Impli

  2026-07-22

  A recent placebo-controlled phase 3 trial demonstrates that mavorixafor, an oral CXCR4 antagonist, significantly improves neutrophil and lymphocyte counts and reduces infection rates in patients with WHIM syndrome. This study represents a critical step toward targeted therapy for this rare combined immunodeficiency, offering new benchmarks for clinical trial design and patient management.

• Inhaled Risedronate Sodium Microspheres Target Emphysema via

  2026-07-21

  The referenced study introduces a novel inhalable Risedronate Sodium-chitosan microsphere formulation, demonstrating targeted deposition in the alveolar region and induction of apoptosis in alveolar macrophages to attenuate pulmonary emphysema. This innovation provides mechanistic insight and a foundation for repurposing bisphosphonates in respiratory disease models, with implications for advanced drug delivery strategies.

• Doxycycline Hyclate as a Matrix Metalloproteinases Inhibitor

  2026-07-21

  Doxycycline hyclate stands out as a research-grade matrix metalloproteinases inhibitor, offering robust protection of blood-brain barrier integrity in neurovascular models. Its validated performance, high solubility, and multi-domain applications make it indispensable for researchers tackling vascular, infectious, and inflammatory pathologies.

• Lactate-GPR81-FARP1-Rac1 Axis Enables Insulin-Independent Gl

  2026-07-20

  This study uncovers a lactate-driven, insulin-independent signaling pathway in skeletal muscle that enhances glucose uptake via GPR81-mediated Rac1 activation. The findings provide mechanistic insights into metabolic adaptations during exercise and suggest new therapeutic targets for hyperglycemia.

• Mavorixafor in WHIM Syndrome: Phase 3 Outcomes and Research

  2026-07-20

  The referenced phase 3 trial demonstrates that mavorixafor, an oral CXCR4 antagonist, effectively increases neutrophil and lymphocyte counts while reducing infection rates in WHIM syndrome patients. This study marks a significant advance in targeted therapy for rare immunodeficiencies and sets a new benchmark for clinical trial rigor in orphan diseases.

• Açaí Extracts: Cytotoxicity and Enzyme Induction in Hepatocy

  2026-07-19

  Raichura et al. present a comprehensive in vitro evaluation of açaí (Euterpe oleracea) extracts on human hepatocyte viability and the modulation of key drug-metabolizing enzymes and transporters. Their findings highlight limited induction potential but underscore dose-dependent cytotoxicity, refining the risk assessment for botanical-drug interactions in hepatocyte models.

• Applied Workflows with Murine Recombinant PDGF-BB: Protocols

  2026-07-18

  PDGF-BB, murine recombinant protein, is the gold standard for driving reproducible cell proliferation and advanced vascular remodeling assays. This article dissects hands-on experimental workflows, troubleshooting strategies, and the translational relevance of PDGF-BB’s mitogenic activity, leveraging recent breakthroughs in pulmonary hypertension research.

• Angiotensin Peptides Modulate SARS-CoV-2 Spike–AXL Interacti

  2026-07-17

  This study demonstrates that specific angiotensin peptides, particularly truncated forms of angiotensin II, enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings reveal an unexpected cross-talk between the renin-angiotensin system and viral entry mechanisms, with implications for understanding COVID-19 pathogenesis and therapeutic targeting.

• Niclosamide: STAT3 Pathway Inhibition and Cancer Research Ut

  2026-07-17

  Niclosamide, a small-molecule STAT3 inhibitor (IC50: 0.7 μM), induces G0/G1 cell cycle arrest and apoptosis in cancer models. Its dual inhibition of STAT3 and NF-κB pathways supports advanced cancer research, with proven in vitro and in vivo efficacy. APExBIO's B2283 formulation is widely adopted for STAT3 signaling studies.

• Liproxstatin-1: Optimizing Ferroptosis Inhibitor Workflows

  2026-07-16

  Liproxstatin-1 is a benchmark ferroptosis inhibitor, enabling precise inhibition of lipid peroxidation in both cellular and animal models. This article provides stepwise protocols, troubleshooting guidance, and insights into sex-specific ferroptosis mechanisms, empowering researchers to achieve robust, reproducible results in advanced ferroptosis research.

16806 records 1/1121 page Next 12345 下5页 Last page